Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy vs Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT04138212Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Overall Survival at 5 years. Started Oct 2019; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04138212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138212.